Lindus Health bets software-first trials can displace the CRO oligopoly

Lindus Health (now Lindus Therapeutics) is a tech-first contract research organization that runs end-to-end clinical trials — protocol design, patient recruitment, data capture, telehealth visits and trial staff — on its Citrus platform, and has expanded into in-licensed drug development.

A software-first CRO can displace the big players by owning the whole trial end-to-end, then convert that execution capability into running its own drug assets.

~$6M in early funding from Creandum, Peter Thiel, Firstminute and Seedcamp; $18M Series A (August 2023); $55M Series B led by Balderton Capital (January 2025); roughly $80M total including grants.

Founded in London in 2021 by Meri Beckwith (ex-OMERS Ventures), Michael Young (former special adviser to the UK Prime Minister on life sciences) and Nik Haldimann, after Beckwith watched healthtech companies struggle with trial outcomes and Young concluded trials were the bottleneck between research and patients. They raised ~$6M from Creandum, Peter Thiel and others before an $18M Series A in August 2023.

By August 2023 Lindus said it had delivered 80+ trials across depression, diabetes and insomnia, touting itself as the 'anti-CRO'. In January 2025 it raised a $55M Series B led by Balderton, with Creandum, Firstminute, Seedcamp and Visionaries Club, reporting 35,000+ patients enrolled and started moving its headquarters from the UK to the US. In March 2025 it launched ReMEdi, a fully virtual Phase 2 trial for ME/CFS with Tiefenbacher Group, using its Citrus eClinical platform, Oura rings for remote monitoring and telehealth visits.

Still running and expanded: by 2026 the company had rebranded as Lindus Therapeutics, adding in-licensed drug asset development on top of its trial execution business; its site claims $80M raised, 45+ completed trials and 120 staff across the US and Europe.

The 'own the entire trial' wedge matched where the pain actually was — end-to-end dysfunction — instead of competing on one feature.

Starting with common, neglected conditions kept trials simple enough for a startup to run end-to-end and made recruitment easier.

ML protocol generation and real-time data monitoring attacked the two most manual, error-prone stages of trial work.

Creandum and Thiel's early checks plus a growing delivered-trial record made the larger 2025 round defensible.

Expanding from CRO services into drug asset development turns execution capability into longer-term upside.

In regulated, relationship-driven industries, software wins as a services business first: Lindus ran whole trials for neglected conditions, then converted that capability into owning drug assets.

As of 2026-09-02 Lindus is scaling as Lindus Therapeutics: it runs 45+ phase I-IV trials across the US, UK and Europe, employs ~120 people, and has expanded into in-licensed drug development with flexible licensing and co-development deal structures. It reports $80M total funding and says 82% of its trials completed enrollment on or ahead of timeline.